CEOs push EU to in­clude cell, gene ther­a­py in­cen­tives in Biotech Act

Last week
Cell/Gene Tx
Law

BioCryst sells Or­ladeyo busi­ness in Eu­rope; UCB gets a Phase 3 win for Fin­tepla

Last week
News Briefing

In­novent brings a new mech­a­nism to obe­si­ty mar­ket with Chi­na ap­proval

Last week
China
Pharma

FDA head Makary’s short-lived CRL ask on KalVista’s drug rais­es more con­cerns of po­lit­i­cal in­ter­ven­tion

Last week
FDA+

Al­pha­bet’s Cal­i­co inks $25M li­cens­ing deal for Mab­well’s IL-11 pro­grams

Last week
Deals
R&D

Bill Meury brings new per­spec­tive to In­cyte as Hop­penot re­tires; Ex-Mor­phoSys CEO leads re­vi­tal­ized Vor Bio

Last week
Peer Review

A din­ner in Paris re­vived talks for Sanofi's $9.5B deal for Blue­print

Last week
Deals
Pharma

Gilead stops RSV an­tivi­ral tri­als af­ter low in­ci­dence rates dur­ing re­cent sea­son

Last week
R&D
Pharma

AI scribes are evolv­ing

Last week
Health Tech

Judge says CVS Care­mark owes $95M in false claims case

Last week
Pharma
Law

De­bate on a long-scru­ti­nized vac­cine in­gre­di­ent con­sumes CDC pan­el in its sec­ond day

Last week
R&D
FDA+

Al­tim­mune posts mixed re­sults for in­cretin drug in MASH; stock is halved

Last week
R&D

Edge­wise de­tails piv­otal plans in Beck­er mus­cu­lar dy­s­tro­phy; Kymera’s $250M of­fer­ing

Last week
News Briefing

Opus, Vi­a­tris say pres­by­opia drug suc­ceeds in Phase 3

Last week
R&D

Why Com­mure, one of health­care's most deal-hun­gry star­tups, plans to buy more scribes

Last week
Startups
Health Tech

Ex­clu­sive: Hand­spring Health rais­es $12M to pro­vide more com­plex youth men­tal health­care

Last week
Financing
Health Tech

Bharat, GSK to cut malar­ia vac­cine price; Emer­gen­t's US stock­pile deal ex­pands

Last week
Manufacturing

Vor Bio bounces back with au­toim­mune drug pact, $175M pri­vate place­ment

Last week
Financing
Deals

No­var­tis strikes car­dio­vas­cu­lar dis­cov­ery deal with Flag­ship’s Pro­Found

Last week
Deals
R&D

Watch Post-Hoc Live: A con­ver­sa­tion about ACIP and the fu­ture of vac­cines

Last week
Editor's note
R&D

Medicare drug spend­ing will slow due to IRA price ne­go­ti­a­tions, CMS econ­o­mists pre­dict 

2 weeks ago
Pharma

Ex-CBER chief Marks crit­i­cizes how FDA craft­ed its new Covid vac­cine frame­work

2 weeks ago
R&D
Pharma

Re­built CDC pan­el will re­assess cu­mu­la­tive vac­cine ef­fects, old­er shots

2 weeks ago
R&D
FDA+

Trump’s CDC nom­i­nee side­steps Sen­ate grilling on con­tro­ver­sial changes

2 weeks ago
People
Pharma
First page Previous page 2345678 Next page Last page
A service from the Financial Times